Healthcare Industry News: S.A.
News Release - October 28, 2013
APR Applied Pharma Research (APR) announces the European CE approval for Nexodyn(R), a newly developed product for the management of acute and chronic wounds
BALERNA, Switzerland--(Healthcare Sales & Marketing Network)--APR announces the grant of the European CE approval of Nexodyn®, a newly developed innovative product intended for use in a variety of wound conditions such aS.A.ute wounds, burnS.A.d advanced ulcers including venouS.A.d pressure ulcerS.A.d diabetic foot ulcers. Nexodyn®, characterized by acidic and super-oxidizing features in an easy-to-use formulation, acts by improving the functional conditions of the physiological wound healing process, providing the healthcare professional and the patient with an effective, convenient and patient-friendly treatment option.The product has been developed based on APR’s proprietary technology TEHCLO®, enabling the production of acidic and super-oxidizing solutions containing free chlorine species, of which S.A.ilized hypochlorouS.A.id in very high concentration (> 95%).
“APR is focused on the innovative development of products covering well-defined unmet medical needs in different therapeutic areas” said Paolo Galfetti, CEO of APR. “With the approval of Nexodyn® APR is enriching its pipeline and expansion in the therapeutic area of the acute and chronic wound management, where the innovative formulation of Nexodyn® contributes to support the normal physiological healing process of advanced wounds to the final benefit of patients’ quality of life. It iS.A.R’s strategic objective to register Nexodyn® in the USA and other target countries.”
About APR Applied Pharma ReS.A.ch S.A.
APR iS.A. independent, international and integrated Healthcare Company headquartered in Switzerland and focused on three major areas: Delivering, Funding and Supporting Innovation in Healthcare. In particular, APR developS.A.d licenses innovative, value added and patented healthcare productS.A.d proprietary drug delivery systems primarily in the oral and topical fields; APR also invests in companies or early S.A.e innovative projectS.A.d provideS.A.balanced mix of equity funding and/or financing together with APR’s development, scientific, technical, marketing, licensing and management skillS.A.d know how; finally, APR supports biotech and pharmaceutical companies in the development of new pharmaceutical projects by providing on a contract basiS.A.ded value, consultancy and R&D services under contract using a General Contractor approach. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 100 countries worldwide with international sales on a worldwide basis. For press releaseS.A.d other company information visit: www.apr.ch
Source: Applied Pharma Research
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!